At the Society of Nuclear Medicine (SNM) 2012, GE Healthcare is showcasing Q.Suite on both the new Discovery* PET/CT 710 and Discovery* PET/CT 610 products. Q.Suite is a collection of next-generation capabilities designed to further quantitative PET by generating more consistent Standardized Uptake Value (SUV) readings — enabling clinicians to assess treatment response accurately, allowing oncologists to modify treatment strategies without waiting for physical results. Effective therapy may help improve the patient’s quality of life and overall outcome as well as reduce the cost burden of ineffective treatment technologies.
Developed in collaboration with leading researchers, Q.Suite represents the next step in GE Healthcare’s vision to enable effective quantitative PET imaging. Its next-generation tools span the workflow today and they provide a foundation for further advancement tomorrow.
The use of PET in therapy assessment is already proven and effective. But by combining the capabilities of Q.Suite with updated clinical practices, we believe the consistency of PET measurements can increase dramatically. The goal is a more personalized care for all patients.
“This is another pivotal year for GE Healthcare as we look to the future of Molecular Imaging,” said Mike Barber, vice president and general manager, Molecular Imaging, GE Healthcare. “Together with our customers, we are focused on improving cost, quality and access in Molecular Imaging—a smarter path to tomorrow’s care. That path means helping clinicians deliver responsible care, both clinically and economically. It requires meaningful collaboration between technology leaders and clinical researchers. And, it enables sustainable advancement on a platform that helps define tomorrow’s care. Every discovery matters, but truly powerful Molecular innovations affect the lives of patients.”
During the course of cancer treatment, clinicians traditionally gauge progress by looking for physical change in the size of a tumor, typically using Computed Tomography (CT) or Magnetic Resonance (MR). However, with quantitative PET imaging, they are also able to consider a tumor’s metabolic activity. In many cases, metabolic changes in a tumor can be perceived earlier than physical ones, so quantitative PET can give physicians an earlier view of how well a treatment is working.
For quantitative PET to be effective, consistency of SUV measurements between a patient’s baseline scan and subsequent follow-up scans is critical. Variation can occur throughout the PET workflow, in areas from patient management and biology to equipment protocols and performance. Controlling these variables to increase consistency can improve the clinician’s confidence that an SUV change has true clinical meaning.
“Doctors are seeking quantitative tools to obtain reproducible measurements over a longitudinal patient study,” said Vivek Bhatt, general manager PET, GE Healthcare. “These tools may enable doctors to assess confidently biological changes in a patient during a course of treatment, allowing them to quickly and accurately modify treatment regimens. These tools could potentially contribute to personalized oncology care, increase quality of patient care and reduce wasted expenditure on ineffective treatment.”
Q.Suite tools for quantitative PET/CT include:
• Q.Freeze-- One image. All the counts. Motion virtually eliminated
Q.Freeze is capable of combining the quantitative benefits of 4D phase-matched PET/CT imaging into a single static image, with the goal to use 100% of counts collected to create the image and ultimately eliminate motion.
• Q.AC-- Attenuation consistency for demanding clinical protocols
GE’s next-generation Q.AC algorithm is designed to reduce potential variance in attenuation correction measurements, helping ensure that the attenuation coefficients used in image reconstruction are accurate.
• Q.Check-- A quality control link between the scanner and workstation
As Data capture is an important component to quantitative PET, Q.Check is designed to provide an additional level of quality control, establishing a link between the console and workstation to ensure that patient and exam data required for quantitative imaging is saved in the patient file before the exam is finished.
• Q.Core-- Accelerating your quantitative imaging workflow
To help address the more sophisticated processing needs of Q.Suite Q.Core is designed to manage both PET acquisition and reconstruction processing at faster speeds—in a compact footprint.
• PET VCAR - Powerful patient monitoring
Visualizing and analyzing disease and treatment response requires powerful tools. PET VCAR provides automated, interactive access to valuable quantitative information, managing multiple lesions and multiple patient exams over time following the most popular treatment response assessment protocols available in PET/CT imaging, including PERCIST. It has the potential to improve the clinicians’ daily reading experience and patient management.
*Trademark General Electric Company
About GE Healthcare
GE Healthcare (gehealthcare.com) provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.
Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries.